Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting a 7% year-on-year (YOY) increase in global group sales to CHF 30.94 billion (USD 39 billion) in constant exchange rate terms. The Pharmaceuticals division drove this growth with a 10% expansion to CHF 23.99 billion (USD 30.24 billion), while the Diagnostics division reported flat growth at CHF 6.96 billion (USD 8.77 billion).
Pharmaceuticals Division Growth Drivers
CEO Thomas Schinecker highlighted the strong growth momentum driven by pharmaceuticals. The top five growth drivers were:
- Phesgo (pertuzumab/trastuzumab/hyaluronidase)
- Vabysmo (faricimab)
- Xolair (omalizumab)
- Hemlibra (emicizumab)
- Ocrevus (ocrelizumab)
These contributed CHF 10.6 billion (USD 13.4 billion) in sales during the six-month period, an increase of CHF 1.7 billion (USD 2.1 billion) from H1 2024.
Geographic Performance
- United States: CHF 12,670 million (52.8% of sales), +10%
- Europe: CHF 4,566 million (19.0% of sales), +5%
- Japan: CHF 1,425 million (5.9% of sales), +5%
- International: CHF 5,324 million (22.3% of sales), +14%
China market sales rose by 9%, driven by the uptake of Phesgo, strong sales of Xofluza (baloxavir marboxil), and the roll-out of Polivy (polatuzumab vedotin) and Vabysmo.
Diagnostics Division Performance
The Diagnostics division’s flat performance was attributed to “the impact of healthcare pricing reforms in China.” This led to a -15% decline in Asia-Pacific sales, offset by a 5% increase in the Europe, Middle East, and Africa (EMEA) region, 6% growth in North America, and 14% expansion in Latin America.-Fineline Info & Tech
